LCM
BMY.RT

Laurion Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Laurion Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-79,763,520
Closed -$10.1M – 950
2020
Q4 		$10.1M Buy
79,763,520
+23,851,492
+43% +$50.8M 0.08% 191
2020
Q3 		$126M Buy
55,912,028
+7,745,865
+16% +$22.1M 1.5% 10
2020
Q2 		$172M Buy
48,166,163
+2,773,581
+6% +$10M 1.94% 7
2020
Q1 		$172M Sell
45,392,582
-4,588,909
-9% -$15.1M 1.88% 11
2019
Q4 		$150M Buy
+49,981,491
New +$130M 1.16% 19

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Laurion Capital Management's BMY.RT Position: Q1 2021 in Review

Laurion Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 79,763,520 shares — an estimated $10.1M sold.

Laurion Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $172M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Laurion Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Laurion Capital Management sold 79,763,520 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $10.1M.
  • Laurion Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Laurion Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $172M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Laurion Capital Management's 13F filing for Q1 2021, filed 14 May 2021.